Protocol Ledger

NCT05003986 · Phase II · RECRUITING

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Interventional Phase II clinical trial protocol NCT05003986 sponsored by Travere Therapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-12 Enrollment: 67 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05003986
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)67 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05003986
Protocol FieldVerified Registry Value
NCT IdentifierNCT05003986
Consolidated Lead SponsorTravere Therapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment67 participants (ESTIMATED)
Registered Start Date2021-08-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05003986
Hospital Research SiteLocationSite Profile
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
Nicklaus Children's HospitalMiami, FLOpen Hospital Dossier ->
C S Mott Children's HospitalAnn Arbor, MIOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI